Before You Buy,is validated on mouse tissue

The intricate signaling pathways within our cells are crucial for a myriad of biological processes, and the Phosphoinositide-3-kinase (PI3K) family plays a pivotal role in these cascades. Specifically, the p110 beta catalytic subunit, also known as PIK3CB or PI3K-beta, is a key component of the class I PI3K signaling pathway. This pathway is implicated in fundamental cellular functions such as cell growth, survival, proliferation, and metabolism. However, dysregulation of PI3K signaling is frequently observed in various diseases, particularly in cancer, making it a significant target for therapeutic intervention. This has led to the development of various PI3K inhibitors, with a particular focus on targeting specific isoforms like p110 beta.

The Significance of the PI3K p110 Beta Isoform

The p110 alpha and p110 beta isoforms are the two most extensively studied members of the class-1A PI3K signaling pathway. Both isoforms are ubiquitously expressed and contribute significantly to cellular signaling. However, research has highlighted the critical importance of the p110 beta isoform. Genetic studies have demonstrated that the p110 beta isoform of PI3K is essential for the growth of PTEN-null tumors. PTEN is a tumor suppressor protein and a negative regulator of PI3K activity; when mutated or lost, it can lead to uncontrolled PI3K signaling. Therefore, selectively blocking PI3K activity, particularly that mediated by p110 beta, represents a promising strategy for cancer therapy.

Mechanisms of PI3K p110 Beta Inhibition

Developing effective PI3K inhibitors involves understanding their mechanism of action. PI3K enzymes are lipid kinases that catalyze the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) by phosphorylating phosphatidylinositol (PI). PIP3 then acts as a crucial second messenger, recruiting proteins with pleckstrin homology (PH) domains to the cell membrane, thereby activating downstream signaling cascades.

PI3K p110 beta peptide inhibitors are designed to interfere with this process. A peptide inhibitor can be understood as a precision research or therapeutic concept aimed at selectively blocking the activity of PI3K. These inhibitors can act through various mechanisms, including binding directly to the catalytic p110 subunit and preventing its enzymatic activity, or by interfering with the binding of PI3K to its activators. For instance, persistent activation of certain protein kinase C (PKC) family members can lead to the phosphorylation of serine residues on PI3K, which can influence its binding to activators and subsequent signaling.

Exploring Specific PI3K p110 Beta Inhibitors

The field of PI3K inhibitor development has seen significant progress. Several compounds are being investigated for their therapeutic potential. For example, BEZ235 is recognized as a potent inhibitor of PI 3-kinase p110 beta, distinguished by its dual action on both PI3K and mTOR pathways. Another example is Apitolisib (GDC-0980, RG7422, GNE 390), a potent class I PI3K inhibitor that targets PI3K alpha, beta, delta, and gamma isoforms with varying potencies (IC50 values of 5 nM, 27 nM, 7 nM, and 14 nM respectively in cell-free assays). Alpelisib (BYL-719) is another notable compound, described as a potent, selective, and orally active PI3K alpha inhibitor that has shown efficacy in targeting PIK3CA-mutated cancers. While these may not be exclusively p110 beta inhibitors, they illustrate the broader efforts in targeting the PI3K pathway.

The development of isoform-selective inhibitors is a key area of research. Understanding that p110 alpha and p110 beta have distinct functions, as observed in myoblasts where PI3K Class-IA p110 alpha and p110 beta exhibit different roles, is crucial for designing targeted therapies. For instance, inhibition of PI3K p110 alpha and PI3K p110 beta can impair downstream signaling, but the specific consequences can vary.

Research Tools and Applications

Beyond therapeutic development, PI3K p110 beta peptide inhibitors and related reagents are invaluable tools for scientific research. Antibodies targeting specific PI3K subunits, such as PI3 Kinase p110 beta Rabbit pAb or PI3K p110 alpha Blocking Peptide, are used to study the expression, localization, and function of these proteins in various experimental settings, including western blots, immunofluorescence, and flow cytometry. These antibodies, often generated by immunizing animals with recombinant fusion proteins or synthetic peptides derived from the target protein, allow researchers